TNF and Crohn disease: Other biological immunomodulators, such as ustekinumab, an mAb against IL12/IL23, showed efficiency in moderately to severely active Crohn’s diseases, and brought clinical benefits in many patients who had failed anti-TNF treatment [36, 37].